Study guide
15.1 Sodium & Water Disorders
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
15.1 Sodium & Water Disorders
Key Takeaways Explain This Topic AI
Hypotonic hyponatraemia must first be differentiated from pseudohyponatraemia (hyperlipidaemia, paraproteinaemia) and hypertonic hyponatraemia (hyperglycaemia; corrected [Na+] = measured [Na+] + 0.3 × [glucose - 5.5]).
Clinical volume assessment guides the differential of hypotonic hyponatraemia: hypovolaemic (urinary Na <30 mmol/L indicates extra-renal losses, >30 mmol/L indicates renal losses/Addison's), euvolaemic (SIADH, hypothyroidism, secondary adrenal insufficiency; urinary Na >30 mmol/L, urine osmolality >100 mOsm/kg), and hypervolaemic (heart failure, cirrhosis, nephrotic syndrome vs acute/chronic kidney disease).
The cornerstone of chronic hyponatraemia management is avoiding Osmotic Demyelination Syndrome (ODS): the safe rate of correction must not exceed 8–10 mmol/L in 24 hours (strictly 4–6 mmol/L/24h in high-risk patients with alcoholism, malnutrition, or advanced cirrhosis).
Acute severe symptomatic hyponatraemia (presenting with seizures, acute coma, or cardiorespiratory arrest) is an immediate medical emergency requiring a 150 mL bolus of intravenous 3% hypertonic saline over 20 minutes, repeatable up to twice to elevate sodium by 4–6 mmol/L and abort cerebral herniation.
Hypernatraemia is managed by calculating total body water deficit and rehydrating with 5% dextrose or 0.45% saline, ensuring serum sodium decreases by no more than 10 mmol/L in 24 hours to prevent fatal rebound cerebral oedema.
Last updated: September 2026
Water balance is governed by hypothalamic osmoreceptors that modulate thirst and arginine vasopressin (AVP / antidiuretic hormone [ADH]) secretion from the posterior pituitary. Serum osmolality is maintained within narrow physiological limits (275–295 mOsm/kg). Serum sodium concentration is an index of water homeostasis , not total body sodium content. Mastery of the diagnostic algorithms for hyponatraemia, safe sodium correction limits, and hypernatraemia is essential for MRCP(UK) Part 1.
- Calculated Serum Osmolality = 2 × [Na+] + [Glucose] + [Urea] (all in mmol/L)
- 1. Initial Diagnostic Triage: Ruling Out Pseudo- and Hypertonic Hyponatraemia
When confronted with a low serum sodium ([Na+] < 135 mmol/L), the first mandatory step is assessing measured serum osmolality to differentiate true hypotonic hyponatraemia from pseudohyponatraemia and hypertonic hyponatraemia. Low Serum Sodium (<135 mmol/L)
- │
- Measure Serum Osmolality
- ┌────────────────────────┼────────────────────────┐
- ▼ ▼ ▼
- Normal Osmolality High Osmolality Low Osmolality
- (275-295 mOsm/kg) (>295 mOsm/kg) (<275 mOsm/kg)
- │ │ │
- Pseudohyponatraemia Hypertonic Hyponatraemia True Hypotonic
- Severe hyperlipidaemia • Hyperglycaemia (DKA/HHS) Hyponatraemia
- Paraproteinaemia • Mannitol infusion │
- (Myeloma, Waldenström) • Translocational shift Assess Volume
- Status
- Normal Serum Osmolality (275–295 mOsm/kg): Pseudohyponatraemia
Pathophysiology: Plasma normally comprises 93% aqueous solution and 7% non-aqueous solid phase (proteins and lipids). Standard laboratory autoanalysers use indirect ion-selective electrodes (ISE) , which dilute the sample by a fixed factor before measurement, assuming normal 7% solids.
In marked hyperlipidaemia (severe hypertriglyceridaemia >15 mmol/L) or profound paraproteinaemia (multiple myeloma, Waldenström's macroglobulinaemia), the non-aqueous solid phase expands to 15–20% of total volume. The aqueous phase sodium concentration is entirely normal, but dilution over-estimates total sample volume, producing an artificially low reported sodium concentration.
Resolution: Measure sodium using direct ISE (available on point-of-care blood gas analysers), which measures electrolyte activity directly in undiluted plasma water and gives the true normal value.
Elevated Serum Osmolality (>295 mOsm/kg): Hypertonic Hyponatraemia
Pathophysiology: Osmotically active solutes confined to the extracellular fluid (ECF)—most commonly glucose in diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS), or exogenous mannitol —draw water out of cells into the ECF via osmosis. This translocational water shift dilutes extracellular sodium.
Correction Formula (Katz / Hillier): Corrected [Na+] = Measured [Na+] + 0.3 × ([Glucose] - 5.5) (In UK practice, for every 10 mmol/L rise in blood glucose above 5.5 mmol/L, serum sodium drops by approximately 3.0 mmol/L). Failure to calculate the corrected sodium can lead to catastrophic mistreatment with hypertonic fluids.
2. True Hypotonic Hyponatraemia: Clinical Volume Assessment
True hypotonic hyponatraemia (<275 mOsm/kg) represents an excess of water relative to sodium. The diagnostic algorithm is organized by bedside clinical assessment of Extracellular Fluid (ECF) volume status combined with spot urinary sodium and urine osmolality :
Volume Status Spot Urine Na (mmol/L) Urine Osmolality (mOsm/kg) Clinical Etiologies Pathophysiology & Management
Hypovolaemic (Tachycardia, postural drop, dry mucous membranes, flat JVP, reduced skin turgor) <30 mmol/L Concentrated (>300–400) Extra-renal losses: Severe diarrhoea, vomiting, burns, pancreatitis, bowel obstruction ('third-spacing') Intravascular volume depletion stimulates carotid/aortic baroreceptors, triggering non-osmotic AVP release and maximal renal sodium retention via aldosterone. Treatment: Intravenous 0.9% sodium chloride rehydration.
Hypovolaemic >30 mmol/L Variable (often <300 or inappropriately concentrated) Renal losses: Thiazide diuretics, loop diuretics, primary adrenal insufficiency (Addison's), Cerebral Salt Wasting (CSW), salt-losing nephropathy Inability of the kidney to retain sodium despite hypovolaemia. Thiazides inhibit DCT sodium reabsorption while preserving medullary concentration. Addison's lacks aldosterone, driving renal natriuresis and hyperkalaemia. Treatment: 0.9% sodium chloride; hydrocortisone and fludrocortisone in Addison's.
Euvolaemic (No oedema, normal JVP, moist mucous membranes, normal blood pressure) >30 mmol/L Concentrated (>100, characteristically >300) SIADH , severe primary hypothyroidism, secondary adrenal insufficiency (isolated ACTH/cortisol deficiency) Mild subclinical volume expansion suppresses aldosterone and stimulates ANP/BNP, promoting natriuresis (>30 mmol/L). Inability to excrete free water due to autonomous AVP. Treatment: Fluid restriction (500–1000 mL/day), oral sodium chloride, demeclocycline, vaptans.
Euvolaemic <30 mmol/L (or variable) Maximally dilute (<100) Psychogenic polydipsia , beer potomania ('tea and toast' diet / low solute intake) Massive free water intake (>10–15 L/day) or extremely low solute intake (<200 mOsm/day) overwhelms renal diluting capacity despite complete physiological suppression of AVP. Treatment: Fluid restriction; gradual reintroduction of dietary solutes.
Hypervolaemic (Peripheral oedema, raised JVP, pulmonary crackles, ascites) <30 mmol/L Concentrated (>300) Congestive heart failure , decompensated liver cirrhosis, nephrotic syndrome Severe reduction in effective arterial blood volume (EABV) activates baroreceptors, triggering non-osmotic AVP release and intense renal sodium reabsorption via RAAS. Treatment: Fluid restriction, dietary sodium restriction, loop diuretics (furosemide).
Hypervolaemic >30 mmol/L Isosthenuric (~300) Acute kidney injury (oliguric) , advanced chronic kidney disease (CKD stage 4–5) Failing nephrons cannot filter or excrete water or sodium. Loss of both concentrating and diluting capacity. Treatment: Fluid restriction, loop diuretics, renal replacement therapy (haemodialysis).
- 3. Syndrome of Inappropriate ADH Secretion (SIADH)
- Diagnostic Criteria (Bartter-Schwartz Criteria)
To establish a diagnosis of SIADH, all of the following core criteria must be fulfilled:
Decreased plasma effective osmolality (<275 mOsm/kg).
Inappropriate urinary concentration (urine osmolality >100 mOsm/kg, characteristically >300 mOsm/kg).
Clinical euvolaemia (no orthostatic hypotension, tachycardia, peripheral oedema, or ascites).
Inappropriate urinary sodium excretion (urinary sodium >30 mmol/L) on normal diet and water intake.
Exclusion of hypothyroidism, hypocortisolaemia (normal Short Synacthen Test), and recent diuretic therapy.
Etiologies of SIADH
Malignancy: Small cell lung cancer (SCLC; responsible for ~70% of paraneoplastic SIADH via autonomous ectopic AVP transcription), head and neck squamous cell carcinomas, lymphoma, pancreatic neuroendocrine tumors.
Central Nervous System (CNS) Disorders: Subarachnoid haemorrhage, subdural haematoma, ischaemic/haemorrhagic stroke, traumatic brain injury, meningitis, encephalitis, brain abscess.
Pulmonary Disorders: Pneumonia (particularly atypical pneumonia such as Legionella pneumophila ), tuberculosis, lung abscess, acute respiratory distress syndrome (ARDS), positive-pressure ventilation.
Pharmacological Agents: Selective serotonin reuptake inhibitors (SSRIs: citalopram, fluoxetine, sertraline), carbamazepine and oxcarbazepine, proton pump inhibitors (PPIs), antipsychotics (haloperidol, risperidone), tricyclic antidepressants, cyclophosphamide, vincristine, and MDMA ('ecstasy').
Tiered Therapeutic Strategy
First-Line: Identify and discontinue offending medications; treat underlying chest infection or malignancy. Implement strict fluid restriction to 500–1000 mL/24 hours . (The Furst ratio, [Urine Na + Urine K] / [Serum Na], predicts responsiveness: if >1.0, fluid restriction alone will fail and pharmacological therapy is required).
Second-Line: Oral sodium chloride tablets (3–6 g/day) combined with oral low-dose furosemide (20–40 mg/day). Furosemide blunts the renal medullary concentrating gradient, promoting free water excretion.
Third-Line: Demeclocycline (600–1200 mg/day in divided doses): A tetracycline antibiotic derivative that induces reversible nephrogenic diabetes insipidus by blocking adenylyl cyclase activation and cAMP generation in collecting duct principal cells. Contraindicated in liver cirrhosis and advanced renal failure due to severe nephrotoxicity.
Vasopressin V2 Receptor Antagonists (Vaptans): Tolvaptan (15 mg once daily oral): Selectively antagonizes collecting duct V2 receptors, inducing pure aquaresis (free water excretion without electrolyte wasting). Requires close inpatient electrolyte monitoring due to the risk of uncontrolled rapid overcorrection; contraindicated in acute severe symptomatic hyponatraemia.
- 4. Sodium Correction Limits & Osmotic Demyelination Syndrome (ODS)
- Pathophysiology of Osmotic Demyelination Syndrome
In chronic hyponatraemia (>48 hours), brain cells adapt to hypotonic extracellular fluid to avoid cerebral oedema by extruding intracellular inorganic ions (sodium, potassium) followed by organic osmolytes (myo-inositol, glutamine, taurine, glutamate). When hypotonic hyponatraemia is corrected too rapidly, the extracellular fluid becomes hypertonic relative to brain parenchymal cells before astrocytes can re-accumulate depleted organic osmolytes. This creates a severe transcellular osmotic gradient, driving rapid dehydrating water efflux from astrocytes into the extracellular space. Astrocytic shrinkage triggers blood-brain barrier breakdown, microvascular endothelial injury, release of inflammatory cytokines, and profound, non-inflammatory demyelination of myelin-rich tracts within the basis pontis ( Central Pontine Myelinolysis [CPM] ) and extrapontine structures ( Extrapontine Myelinolysis [EPM] : basal ganglia, thalamus, internal capsule). Chronic Hyponatraemia (>48h) ──► Astrocytes lose organic osmolytes to prevent swelling
- │
- RAPID INTRAVENOUS REHYDRATION / CORRECTION
- │
- ▼
- Hypertonic extracellular fluid pulls water from brain cells
- │
- ▼
- Astrocyte dehydration ──► Blood-brain barrier rupture
- │
- ▼
- Oligodendrocyte apoptosis & demyelination of basis pontis
- │
- ▼
- OSMOTIC DEMYELINATION SYNDROME (Locked-in Syndrome, Spastic Quadriparesis)
- Clinical Presentation of ODS
Characteristically exhibits a biphasic course : the patient initially improves neurologically as serum sodium rises, but 2 to 6 days later develops progressive, irreversible neurological deterioration: dysarthria, dysphagia, horizontal gaze palsy, spastic quadriparesis, pseudobulbar palsy, and classical 'locked-in' syndrome (complete anarthria and quadriplegia with preserved cognitive awareness and intact vertical eye movements). MRI of the brain (T2/FLAIR) demonstrates classic high signal intensity in the central pons sparing the periphery.
Safe Correction Limits
Standard Risk: Serum sodium correction must not exceed 8–10 mmol/L in any 24-hour period , and <18 mmol/L in 48 hours.
High-Risk Patients: Correction must be restricted to 4–6 mmol/L in 24 hours (maximum 8 mmol/L in 24 hours). High-risk factors include: chronic alcohol dependence, severe malnutrition, advanced liver cirrhosis, hypokalaemia, and baseline serum sodium <105 mmol/L.
Rescue Protocol for Accidental Overcorrection
If the sodium correction rate exceeds the safe threshold, therapeutic re-lowering must be initiated immediately:
Discontinue all sodium-containing intravenous infusions and diuretics.
Infuse intravenous 5% Dextrose in water (D5W) at 10 mL/kg over 2 hours under hourly sodium monitoring.
Administer Desmopressin (DDAVP) 1–2 mcg IV or SC every 6 to 8 hours to arrest renal free water clearance and re-clamp serum sodium.
5. Severe Acute Symptomatic Hyponatraemia Protocol
Severe acute hyponatraemia (<48 hours duration or acute presentation with neuro-emergencies) produces massive cerebral oedema because the brain has not had time to extrude organic osmolytes. Manifestations include generalized tonic-clonic seizures, coma (GCS ≤ 8), respiratory arrest, and signs of transtentorial herniation.
Immediate Emergency Action: Administer an intravenous bolus of 150 mL of 3% Hypertonic Saline (NaCl) over 20 minutes (or 2 mL/kg).
Re-check serum sodium immediately. If severe neurological symptoms persist, repeat the 150 mL 3% hypertonic saline bolus once or twice (maximum three boluses).
Target: A rapid elevation of serum sodium by 4–6 mmol/L acutely . This small increment reduces brain volume by ~10%, aborts cerebral herniation, and terminates seizures.
Once severe symptoms resolve or the 4–6 mmol/L target is reached, cease hypertonic saline and adhere strictly to the 24-hour ceiling (8–10 mmol/L total rise).
6. Hypernatraemia: Water Deficit & Safe Rehydration
Hypernatraemia ([Na+] > 145 mmol/L) always indicates hyperosmolality and a deficit of total body water relative to sodium. Causes include unreplaced insensible fluid losses (sweating, burns, tachypnoea) paired with impaired thirst or impaired access to water (elderly, infants, ventilated ICU patients), central or nephrogenic diabetes insipidus, osmotic diuresis (HHS/DKA, mannitol), and severe osmotic diarrhoea.
Total Body Water Deficit Calculation
Water Deficit (L) = Total Body Water (TBW) × ([Na+] / 140 - 1) TBW = 0.6 × Weight (kg) in adult males (0.5 × Weight in females and elderly)
Safe Rate of Correction
In chronic hypernatraemia (>48 hours), brain cells accumulate idiogenic organic osmolytes to prevent cellular dehydration. Rapid reduction of serum sodium creates an osmotic gradient directing water into brain cells, causing fatal cerebral oedema, brain herniation, and intractable seizures .
Correction Ceiling: Serum sodium must decrease by no more than 10 mmol/L per 24 hours (target rate ~0.5 mmol/L/hour).
Fluids: Oral or nasogastric free water is preferred. If intravenous fluids are required, use 5% Dextrose (D5W) or 0.45% Sodium Chloride (half-normal saline).